Logo image of ETON

ETON PHARMACEUTICALS INC (ETON) Stock Fundamental Analysis

NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD

17.68  +0.36 (+2.08%)

After market: 17.5 -0.18 (-1.02%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ETON. ETON was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of ETON is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ETON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ETON has reported negative net income.
ETON had a positive operating cash flow in the past year.
ETON had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ETON reported negative operating cash flow in multiple years.
ETON Yearly Net Income VS EBIT VS OCF VS FCFETON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

ETON has a better Return On Assets (-15.29%) than 66.67% of its industry peers.
ETON has a better Return On Equity (-34.30%) than 65.59% of its industry peers.
Industry RankSector Rank
ROA -15.29%
ROE -34.3%
ROIC N/A
ROA(3y)-15.37%
ROA(5y)-51.94%
ROE(3y)-28.71%
ROE(5y)-87.68%
ROIC(3y)N/A
ROIC(5y)N/A
ETON Yearly ROA, ROE, ROICETON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

ETON's Gross Margin of 59.30% is fine compared to the rest of the industry. ETON outperforms 66.13% of its industry peers.
ETON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETON Yearly Profit, Operating, Gross MarginsETON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ETON has been increased compared to 1 year ago.
ETON has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ETON has been reduced compared to a year ago.
ETON Yearly Shares OutstandingETON Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ETON Yearly Total Debt VS Total AssetsETON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

ETON has an Altman-Z score of 10.57. This indicates that ETON is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 10.57, ETON belongs to the best of the industry, outperforming 86.56% of the companies in the same industry.
ETON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.57
ROIC/WACCN/A
WACC9.75%
ETON Yearly LT Debt VS Equity VS FCFETON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.51 indicates that ETON should not have too much problems paying its short term obligations.
ETON has a worse Current ratio (1.51) than 73.12% of its industry peers.
A Quick Ratio of 1.41 indicates that ETON should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.41, ETON is doing worse than 68.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.41
ETON Yearly Current Assets VS Current LiabilitesETON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

ETON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -400.00%.
Looking at the last year, ETON shows a small growth in Revenue. The Revenue has grown by 5.63% in the last year.
Measured over the past years, ETON shows a very strong growth in Revenue. The Revenue has been growing by 824.84% on average per year.
EPS 1Y (TTM)-400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
Revenue 1Y (TTM)5.63%
Revenue growth 3Y824.84%
Revenue growth 5YN/A
Sales Q2Q%46.9%

3.2 Future

ETON is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 95.91% yearly.
The Revenue is expected to grow by 39.30% on average over the next years. This is a very strong growth
EPS Next Y-129.5%
EPS Next 2Y202.32%
EPS Next 3Y150.77%
EPS Next 5Y95.91%
Revenue Next Year18.53%
Revenue Next 2Y46.07%
Revenue Next 3Y45.64%
Revenue Next 5Y39.3%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ETON Yearly Revenue VS EstimatesETON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ETON Yearly EPS VS EstimatesETON Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ETON. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 41.27 indicates a quite expensive valuation of ETON.
Based on the Price/Forward Earnings ratio, ETON is valued a bit cheaper than 76.88% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ETON to the average of the S&P500 Index (92.56), we can say ETON is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 41.27
ETON Price Earnings VS Forward Price EarningsETON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ETON Per share dataETON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

ETON's earnings are expected to grow with 150.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y202.32%
EPS Next 3Y150.77%

More info and screens

0

5. Dividend

5.1 Amount

ETON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ETON PHARMACEUTICALS INC

NASDAQ:ETON (1/31/2025, 8:29:02 PM)

After market: 17.5 -0.18 (-1.02%)

17.68

+0.36 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners33.16%
Inst Owner Change-0.17%
Ins Owners5.39%
Ins Owner Change2.48%
Market Cap470.82M
Analysts82.5
Price Target26.18 (48.08%)
Short Float %0.97%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)163.03%
Min EPS beat(2)-68.07%
Max EPS beat(2)394.12%
EPS beat(4)2
Avg EPS beat(4)60.03%
Min EPS beat(4)-120.59%
Max EPS beat(4)394.12%
EPS beat(8)6
Avg EPS beat(8)113.25%
EPS beat(12)7
Avg EPS beat(12)32.9%
EPS beat(16)8
Avg EPS beat(16)20.49%
Revenue beat(2)2
Avg Revenue beat(2)2.75%
Min Revenue beat(2)1.09%
Max Revenue beat(2)4.4%
Revenue beat(4)2
Avg Revenue beat(4)-0.94%
Min Revenue beat(4)-6.89%
Max Revenue beat(4)4.4%
Revenue beat(8)5
Avg Revenue beat(8)11.57%
Revenue beat(12)6
Avg Revenue beat(12)-2.77%
Revenue beat(16)6
Avg Revenue beat(16)-14.15%
PT rev (1m)0%
PT rev (3m)42.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-200%
EPS NY rev (1m)0%
EPS NY rev (3m)10%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.23%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)2.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 41.27
P/S 13.58
P/FCF N/A
P/OCF 222.19
P/B 29.46
P/tB 46.49
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)0.43
Fwd EY2.42%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.08
OCFY0.45%
SpS1.3
BVpS0.6
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.29%
ROE -34.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.3%
FCFM N/A
ROA(3y)-15.37%
ROA(5y)-51.94%
ROE(3y)-28.71%
ROE(5y)-87.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 250.19%
Cap/Sales 7.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.41
Altman-Z 10.57
F-Score3
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)317.45%
Cap/Depr(5y)274.23%
Cap/Sales(3y)10.17%
Cap/Sales(5y)69.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
EPS Next Y-129.5%
EPS Next 2Y202.32%
EPS Next 3Y150.77%
EPS Next 5Y95.91%
Revenue 1Y (TTM)5.63%
Revenue growth 3Y824.84%
Revenue growth 5YN/A
Sales Q2Q%46.9%
Revenue Next Year18.53%
Revenue Next 2Y46.07%
Revenue Next 3Y45.64%
Revenue Next 5Y39.3%
EBIT growth 1Y-259.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.22%
EBIT Next 3Y139.99%
EBIT Next 5YN/A
FCF growth 1Y94.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.48%
OCF growth 3YN/A
OCF growth 5YN/A